Gail M. Farfel, Chief Clinical Development & Reg Offic at MARINUS PHARMACEUTICALS INC (MRNS), sold 30,000 shares at $9.48 ($284K) on 2015-04-21, disclosed to the SEC on 2015-04-23.
Scheduled sale ($284k) by Chief Clinical Development & Reg Offic under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| DRRX | BUY | 2022-05-18 | $22K | — | Filing → |
| DRRX | BUY | 2022-05-13 | $8K | — | Filing → |
| DRRX | BUY | 2022-05-12 | $959 | — | Filing → |